VIDEO: Destiny 04 Trial results have potential to be ‘practice changing’ for breast cancer
Click Here to Manage Email Alerts
In this video, Kevin Kalinsky, MD, an associate professor of medicine at New York-Presbyterian Hospital/Columbia University Medical Center, discussed the Destiny 04 Trial presented at 39th Miami Breast Cancer Conference.
According to a press release, treatment with trastuzumab deruxtecan improved PFS and OS in patients with HER2-low unresectable and metastatic breast cancers compared with chemotherapy.
"This has the potential for being practice changing. At Miami Breast this time next year, I suspect our paradigm of treating patients with metastatic triple-negative breast cancer, as well as patients with metastatic hormone receptor-positive HER2-low disease, will shift," Kalinsky said.
Collapse
Read more about
Click Here to Manage Email Alerts